Patent lawsuit over Perrigo’s Monistat-1 dismissed
ALLEGAN, Mich. Perrigo on Thursday announced that the Hatch-Waxman litigation relating to Miconazole Nitrate Vaginal Cream and Suppository between Johnson & Johnson and Perrigo has been dismissed. Accordingly, Perrigo plans to launch a store brand version of the Monistat-1 Combination Pack following Food and Drug Administration approval, the company reported.
“This is another example of Perrigo’s commitment to continue bringing new store brand products to the market, stated Perrigo president and chief executive officer Joe Papa. “The one-day Miconazole cream and suppository introduction to the store brand market provides an important new product in the feminine hygiene category to our retail and wholesale customers while providing significant savings for the consumer. Perrigo is working every day to make quality healthcare more affordable.”
Earlier this year, Perrigo had been sued by Johnson & Johnson’s McNeil unit for infringement of a patent related to Perrigo’s filing of an ANDA for a generic to Monistat-1 Combination Pack in the United States District Court for the District of New Jersey.
Monistat-1 has annual retail sales of approximately $80 million dollars, Perrigo reported. The dismissal of the lawsuit ends the 30 month Hatch-Waxman stay period, which was originally set to expire in September 2010. Perrigo expects its pending launch to have 180 day first-to-file exclusivity.
CRN study finds that nearly four-fifths of doctors recommend supplements
WASHINGTON The majority of physicians—79 percent—recommend supplements to their patients, according to the “Life…supplemented” Healthcare Professionals Impact Study, conducted by the Council for Responsible Nutrition, that was released Wednesday.
Bone health was the leading health reason physicians recommend supplements—33 percent of physicians recommended bone health supplements to their patients—followed by supplements for overall health, joint health, heart health and to maintain a healthy cholesterol.
FDA announces meeting to explore OTC flu treatments
ROCKVILLE, Md. Treatments to be used in the event of a pandemic flu epidemic may one day be available over-the-counter. The Food and Drug Administration on Tuesday announced a joint meeting of the Antiviral Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee in the Federal Register to determine the types of studies and trial designs needed for an influenza antiviral MedKit for the treatment or prevention of pandemic influenza.
The meeting will be held Oct. 29 at the Hilton in Rockville, Md.
According to the announcement, committee members will be tasked with providing advice on issues such as the role of personal MedKits, home stockpiling, non-prescription availability of influenza medications and interfaces of home readiness with public health systems.